OTC · Biotechnology

Bavarian Nordic A/S (BVNKF) Stock

$27.69 +0.00% OTC: BVNKF Healthcare

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer.

Valuation

MetricValue
Price$27.69
Market Cap$2.14B
P/E Ratio12.19
P/B Ratio1.08
P/S Ratio2.28
EPS (TTM)$2.27
52-Week High$37.60
52-Week Low$27.69
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE9.25%
ROA8.32%
ROCE11.39%
Gross Margin47.40%
Operating Margin25.36%
Net Margin19.83%
Debt/Equity0.01
Current Ratio6.47

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.9B$3.2B$7.1B$5.7B$6.2B
Operating Profit$-263.0M$-4.0M$1.5B$940.0M$919.0M
Net Profit$-465.0M$-347.0M$1.5B$988.0M$1.4B
EPS$-7.37$-4.93$19.23$12.60$17.61
Op Margin-13.9%-0.1%21.3%16.4%14.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.1B$12.4B$14.4B$14.4B$14.9B
Total Liabilities$4.7B$5.2B$4.0B$3.0B$2.1B
Cash$592.0M$575.0M$1.5B$1.6B$1.7B
Borrowings$1.1B$1.8B$145.0M$128.0M$131.0M

Latest News

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil GlobeNewswire · Jul 13, 2026 Bavarian Nordic – Completion of Share Buy-Back Program GlobeNewswire · Jul 13, 2026 Bavarian Nordic – Transactions in Connection with Share Buy-Back Program GlobeNewswire · Jul 6, 2026 Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine GlobeNewswire · Jun 29, 2026 Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine GlobeNewswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-358.0M$220.0M$1.1B$1.9B$2.7B
Investing Cash Flow$-3.9B$-2.3B$-1.9B$-3.6B$-2.7B
Financing Cash Flow$-86.0M$-31.0M$-52.0M$-69.0M$-191.0M
Net Cash Flow$306.0M$-16.0M$902.0M$146.0M$282.0M
Free Cash Flow$-1.4B$-1.2B$142.0M$262.0M$2.5B

Valuation & Return Ratios

MetricValue
PEG Ratio-0.95
EV / EBITDA5.75
FCF Yield10.21%
Quick Ratio3.58
Interest Coverage128.19
Return 1Y-4.19%
Return 3Y2.03%
Return 5Y-39.80%

Ownership

Insiders Held0.05%
Institutions Held32.33%
Institutions Float Held32.34%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1,131,2362026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund761,6312026-03-31
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.630,0062026-04-30
iShares Trust-iShares Core MSCI EAFE ETF578,5962026-06-30
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.467,1752026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRCTFBioArctic AB (publ) $31.78 -9.20% 125.73 $2.82B 2.61%
GLPGFLakefront Biotherapeutics $28.08 +0.00% 3.47 $1.85B 0.00%
HAWPYHaw Par Corporation Limited $53.50 +0.00% 13.52 $2.96B 1.16%
HBMHFHBM Holdings Limited $1.56 +0.00% 23.09 $1.30B 0.00%
HYPMYHypera S.A. $4.00 -0.93% 7.63 $2.82B 5.00%

About Bavarian Nordic A/S

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S is headquartered in DK.

Bavarian Nordic A/S (BVNKF) stock trades at $27.69 with a market capitalization of $2.14B. The stock is valued at a price-to-earnings (P/E) ratio of 12.19, price-to-book of 1.08, price-to-sales of 2.28. Over the past 52 weeks the stock has ranged between $27.69 and $37.60, and currently trades 26.4% below its 52-week high.

On profitability, Bavarian Nordic A/S generates a return on equity (ROE) of 9.25%, return on capital employed of 11.39%, an operating margin of 25.36%, a net profit margin of 19.83%.

Official website: www.bavarian-nordic.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides